Gates Foundation Pledges $120 Million to Help Get Merck Covid Pills to Poor Countries

 26 total views,  1 views today

Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.

From: New York Times